Unlocking biomedical breakthroughs
MRC, GSK and five leading UK universities collaborate to crack difficult disease areas with support from NIHR
Medical Research Council (MRC) and GlaxoSmithKline (GSK) and five leading UK universities collaborate to crack difficult disease areas
MRC and GSK are to collaborate on a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients. The collaboration will be supported by the NIHR Cambridge Biomedical Research Centre, the NIHR Newcastle Biomedical Research Centre, the NIHR Imperial Biomedical Research Centre and the NIHR University of College London Hospitals Biomedical Research Centre.
The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL, with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases. It is hoped that combining the disease biology expertise of these academic scientists with GSK’s drug development expertise and resources will ultimately lead to breakthroughs in understanding that could accelerate the development of innovative treatments for patients.
Minister for Life Sciences George Freeman said “Networks of biomedical researchers from hospitals, industry and universities are key to unlocking the biomedical breakthroughs that are transforming our understanding of the mechanisms of disease and developing new diagnostics and treatments for patients.”
More articles Posted on: 16 July 2015